For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:
https://www.mycme.com/courses/new-approaches-to-menopausal-vms-9462

Summary
This CME podcast explores the latest advancements in managing menopausal vasomotor symptoms (VMS). Join Dr. Genevieve Neil-Perry as she discusses the biology of VMS, highlighting the role of KNDy neurons and neurokinin B. Discuss evidence-based treatments, including the new NK3 receptor antagonists and their clinical data. Gain practical insights into tailoring treatment to individual patient needs and addressing the unique challenges faced by women entering menopause.

Learning Objectives
Upon completion of this activity, learners should be able to: 

• Discuss the biology of menopausal VMS
• Integrate new and emerging agents into the treatment of women with menopausal VMS, based on patient characteristics and preferences

This activity is accredited for CME/CE Credit
The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The National Association for Continuing Education designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.50 contact hours (which includes 0.25 hours of pharmacology).

For additional information about the accreditation of this program, please contact NACE at [email protected].

Summary of Individual Disclosures
Please review faculty and planner disclosures here.

Disclosure of Commercial Support
This educational activity is supported by an independent medical educational grant from Astellas Pharma Global Development, Inc.

Please visit http://naceonline.com to engage in more live and on demand CME/CE content.